journal
MENU ▼
Read by QxMD icon Read
search

Leukemia & Lymphoma

journal
https://www.readbyqxmd.com/read/28535112/is-hbv-prophylaxis-required-during-cll-treatment-with-ibrutinib
#1
Alessandra Tedeschi, Anna Maria Frustaci, Maddalena Mazzucchelli, Roberto Cairoli, Marco Montillo
No abstract text is available yet for this article.
May 23, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28535095/managing-cns-disease-in-adults-with-acute-lymphoblastic-leukemia
#2
Richard A Larson
The central nervous system (CNS) is an important site of involvement by acute lymphoblastic leukemia (ALL) in adults. The prevalence is sufficiently high that prophylactic treatment is routinely given to this sanctuary site in order to eradicate occult disease that might otherwise lead to a relapse. A lumbar puncture should be routinely performed in all newly diagnosed patients with ALL. The risks of CNS leukemia vary by phenotype and genotype. Preventive treatment of the CNS during post-remission therapy has become an integral part of all current ALL treatment protocols...
May 23, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28535087/cytotoxic-t-cells-in-chronic-idiopathic-neutropenia-express-restricted-antigen-receptors
#3
Semeli Mastrodemou, Evangelia Stalika, Anna Vardi, Katerina Gemenetzi, Michalis Spanoudakis, Maria Karypidou, Irene Mavroudi, Anastasia Hadzidimitriou, Catherine Stavropoulos-Giokas, Helen A Papadaki, Kostas Stamatopoulos
Chronic idiopathic neutropenia (CIN) is an acquired disorder of granulopoiesis characterized by female predominance and mostly uncomplicated course. Crucial to CIN pathophysiology is the presence of activated T lymphocytes with myelosuppressive properties in both peripheral blood (PB) and bone marrow (BM). We systematically profiled the T cell receptor beta chain (TRB) gene repertoire in CD8(+) cells of 34 CIN patients through subcloning/Sanger sequencing analysis of TRBV-TRBD-TRBJ gene rearrangements. Remarkable repertoire skewing and oligoclonality were observed, along with shared clonotypes between different patients, alluding to antigen selection...
May 23, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28535082/evaluating-early-interim-fluorine-18-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-with-the-suvmax-liver-based-interpretation-for-predicting-the-outcome-in-diffuse-large-b-cell-lymphoma
#4
Yang Fan, Yuewei Zhang, Zhi Yang, Zhitao Ying, Nina Zhou, Chen Liu, Yuqin Song, Jun Zhu, Xuejuan Wang
Interim (18)F-FDG PET/CT is an effective predictor in patients with DLBCL, but the standard evaluating criteria were controversial. In this study, investigators tried to investigate whether the liver SUVmax (SUVmax-liver)-based interpretation could improve the accuracy of predicting the outcomes, comparing with the Deauville five-point scale (5-PS) and the reduction rate of the maximum standardized uptake value (ΔSUVmax) criteria. In 119 patients, PET/CT after two chemotherapy cycles (PET2) were evaluated with the SUVmax-liver-based interpretation, 5-PS, and ΔSUVmax criteria...
May 23, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28535080/diagnostic-value-of-serum-ferritin-and-cytokine-profiles-of-hemophagocytic-syndrome-following-allogeneic-hematopoietic-cell-transplantation-methodological-issues
#5
https://www.readbyqxmd.com/read/28509630/mrd-in-aml-a-role-for-detecting-leukemic-blasts-at-day-14-post-induction-chemotherapy
#6
Michael Kluk
No abstract text is available yet for this article.
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28509595/phase-ii-study-of-intensified-rituximab-induction-and-maintenance-for-low-grade-b-cell-lymphoma
#7
Hirokazu Nagai, Takeshi Shimomura, Makoto Takeuchi, Shuichi Hanada, Takuya Komeno, Kazutaka Sunami, Michihiro Hidaka, Takahiro Yano, Kiyoshi Kitano, Isao Yoshida, Nobumasa Inoue, Akiko Saito, Keizo Horibe, Suzuko Motitani, Shu Ichihara, Tomoyuki Watanabe, Morio Sawamura
Rituximab has markedly improved the outcomes of B cell lymphoma, and its maintenance has been shown to be beneficial in low grade B cell lymphoma (LGBCL). We conducted a multicenter, phase II trial of intensive rituximab induction and maintenance therapy for LGBCL to optimize the rituximab monotherapy. Patients with newly diagnosed or rituximab naïve relapsed LGBCL received 8 weekly rituximab as induction, then continued maintenance therapy with rituximab for 4 weeks at 6-month intervals. The primary endpoint was the overall response rate (ORR)...
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28509594/g-csf-improves-safety-when-you-start-the-day-after-autologous-transplant-in-multiple-myeloma
#8
Douglas W Sborov, Yu Kyoung Cho, Francesca Cottini, Erinn M Hade, Misty Lamprecht, Karen Tackett, Nidhi Sharma, Nita Williams, Junan Li, Steven Devine, Ming Poi, Mitch A Phelps, Craig C Hofmeister
No abstract text is available yet for this article.
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28509593/impact-of-pharmacokinetics-on-the-toxicity-and-efficacy-of-clofarabine-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia
#9
Bozena Büttner, Holger Knoth, Michael Kramer, Reinhard Oertel, Andreas Seeling, Katja Sockel, Malte von Bonin, Friedrich Stölzel, Nael Alakel, Uwe Platzbecker, Christoph Röllig, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Jan Moritz Middeke
Common side effects of clofarabine (CFB) are liver toxicity, particularly a transient elevation of transaminases and skin toxicity. We studied the correlation of pharmacokinetic (PK) parameters with these toxicities and the efficacy of CFB in patients with relapsed or refractory acute myeloid leukemia. Clofarabine PK parameters showed large inter-individual variability. A higher CFB area under the curve was significantly associated with higher transaminase levels (p = .011 for aspartate aminotransferase (AST), adjusted for age, sex, cumulated CFB dosage, baseline AST, and glomerular filtration rate (GFR))...
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28509586/long-term-persistent-donor-recipient-mixed-chimerism-without-disease-recurrence-after-myeloablative-single-unit-cord-blood-transplantation-in-adult-acute-myeloid-leukemia-following-myelodysplastic-syndrome
#10
Susumu Tanoue, Takaaki Konuma, Satoshi Takahashi, Eri Watanabe, Natsuko Sato, Nobukazu Watanabe, Masamichi Isobe, Seiko Kato, Jun Ooi, Arinobu Tojo
No abstract text is available yet for this article.
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28509585/identification-of-a-novel-fusion-tbl1xr1-pdgfrb-in-a-patient-with-acute-myeloid-leukemia-harboring-the-dek-nup214-fusion-and-clinical-response-to-dasatinib
#11
Paulo Vidal Campregher, Nathalia da Silva Halley, Gabriela Amaral Vieira, Juliana Folloni Fernandes, Elvira Deolinda Rodrigues Pereira Velloso, Siraj Ali, Tariq Mughal, Vincent Miller, Cristovão Luis Pitangueira Mangueira, Vicente Odone, Nelson Hamerschlak
No abstract text is available yet for this article.
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28509582/tariquidar-sensitizes-multiple-myeloma-cells-to-proteasome-inhibitors-via-reduction-of-hypoxia-induced-p-gp-mediated-drug-resistance
#12
Barbara Muz, Hubert D Kusdono, Feda Azab, Pilar de la Puente, Cinzia Federico, Mark Fiala, Ravi Vij, Noha N Salama, Abdel Kareem Azab
Multiple myeloma (MM) presents a poor prognosis and high lethality of patients due to development of drug resistance. P-glycoprotein (P-gp), a drug-efflux transporter, is upregulated in MM patients post-chemotherapy and is involved in the development of drug resistance since many anti-myeloma drugs (including proteasome inhibitors) are P-gp substrates. Hypoxia develops in the bone marrow niche during MM progression and has long been linked to chemoresistance. Additionally, hypoxia-inducible transcription factor (HIF-1α) was demonstrated to directly regulate P-gp expression...
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28509580/use-of-minimal-residual-disease-assessment-in-the-treatment-of-chronic-lymphocytic-leukemia
#13
Carolyn Owen, Anna Christofides, Nathalie Johnson, Tatiana Lawrence, David MacDonald, Carol Ward
Progress in chronic lymphocytic leukemia (CLL) therapies has extended greatly the length and depth of remission, with the goal of treatment advancing towards a cure for some patients. Accordingly, clinical endpoints must evolve to capture these outcomes, and to provide faster access to novel therapies. Minimal residual disease (MRD) is an important endpoint representing more accurately the depth of remission than complete response (CR), and is highly prognostic of progression-free survival (PFS) and overall survival (OS)...
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28509575/haploidentical-hematopoietic-stem-cell-transplantation-with-myeloablative-conditioning-regimen-could-serve-as-an-optional-salvage-therapy-for-younger-patients-with-refractory-or-relapsed-aggressive-non-hodgkin-lymphoma
#14
Xiaofang Xiao, Haiwen Huang, Jia Chen, Yibin Jiang, Lihong Zhang, Yang Xu, Ting Xu, Xiaochen Chen, Caixia Li, Zhengming Jin, Jia Ruan, Depei Wu
No abstract text is available yet for this article.
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28508728/high-frequency-of-identical-clonal-immunoglobulin-dna-in-pre-treatment-tumor-and-plasma-from-untreated-patients-with-hiv-associated-lymphoma-prospective-multicenter-trial-of-the-aids-malignancies-consortium-amc-064
#15
Nina D Wagner-Johnston, Shelly Lensing, Ariela Noy, Lee Ratner, David Henry, Jeannette Y Lee, Sylvia Silver, Malek Faham, Richard F Ambinder
Patients with HIV are at increased risk for developing B-cell lymphomas likely due in part to chronic antigen stimulation leading to clonal immunoglobulin (Ig) gene rearrangements. Next-generation sequencing (NGS)-based identification of circulating Ig clonotypes has not been well-characterized in HIV-related lymphomas. The AIDS Malignancies Consortium (AMC) enrolled 51 untreated patients with HIV-related B-cell lymphomas and analyzed paired tumor/plasma specimens for Ig clonotypes using an NGS approach (AMC064, NCT00981097)...
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28508718/frondoside-a-induces-aif-associated-caspase-independent-apoptosis-in-burkitt-lymphoma-cells
#16
Sergey A Dyshlovoy, Stefanie Rast, Jessica Hauschild, Katharina Otte, Winfried H Alsdorf, Ramin Madanchi, Vladimir I Kalinin, Alexandra S Silchenko, Sergey A Avilov, Judith Dierlamm, Friedemann Honecker, Valentin A Stonik, Carsten Bokemeyer, Gunhild von Amsberg
For patients with refractory or relapsed Burkitt lymphoma (BL), no standard therapy is available for second-line treatment to date. Nonfunctional caspases-dependent apoptosis pathways, inactivating p53 mutations and pro-survival autophagy prevent activity of conventional chemotherapy. Thus, new drugs bypassing these mechanisms of resistance are required. Here, we investigated the efficacy of the marine natural compound frondoside A (FrA) in eight BL cell lines. FrA revealed cytotoxic effects in all cell lines tested including the multiresistant CA46 cells...
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28508692/seifem-2010-e-economic-evaluation-of-posaconazole-for-antifungal-prophylaxis-in-patients-with-acute-myeloid-leukemia-receiving-induction-chemotherapy
#17
Alessandro Busca, Federica Lessi, Luisa Verga, Anna Candoni, Chiara Cattaneo, Simone Cesaro, Giulia Dragonetti, Mario Delia, Alessio De Luca, Gaspare Guglielmi, Mario Tumbarello, Giordana Martino, Gianpaolo Nadali, Rosa Fanci, Marco Picardi, Leonardo Potenza, Annamaria Nosari, Franco Aversa, Livio Pagano
Posaconazole demonstrated clinical superiority over fluconazole and itraconazole for prophylaxis of mold infections, although concerns exist regarding the high acquisition cost for posaconazole. In this respect, we sought to analyze the costs of antifungal prophylaxis in patients with acute myeloid leukemia (AML) who received prophylactic posaconazole (n = 510, 58%), itraconazole (n = 120, 14%) or fluconazole (n = 175, 20%) during induction chemotherapy. The estimated cost of antifungal prophylaxis as well as the costs of subsequent systemic antifungal therapy for treatening an invasive fungal infections (IFI) was higher in the posaconazole group compared to itraconazole and fluconazole groups...
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28504035/bleomycin-pulmonary-toxicity-does-not-adversely-affect-the-outcome-of-patients-with-hodgkin-lymphoma
#18
Haowei Linda Sun, Eshetu G Atenafu, Richard Tsang, Vishal Kukreti, Theodore K Marras, Michael Crump, John Kuruvilla
Bleomycin pulmonary toxicity (BPT) is a well-described complication of bleomycin-containing regimens. Previous data on risk factors and the impact of BPT on survival in Hodgkin lymphoma (HL) were conflicting. We reviewed 253 HL patients treated with adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) at the Princess Margaret Hospital from 1999 to 2009 to examine the incidence and risk factors for BPT, and the effect of BPT on survival. BPT was defined by pulmonary symptoms, bilateral interstitial infiltrates on computed tomography, and the absence of infection...
May 15, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28504033/salvage-chemotherapy-and-autologous-stem-cell-transplantation-for-peripheral-t-cell-lymphoma-a-subset-analysis-of-the-canadian-cancer-trials-group-ly-12-randomized-phase-3-study
#19
Tanya Skamene, Michael Crump, Kerry J Savage, Tony Reiman, John Kuruvilla, David Good, David LeBrun, Ralph M Meyer, Laurie H Sehn, Denis Soulières, Julie Stakiw, Nicole Laferriere, Stefano Luminari, Lois E Shepherd, Marina Djurfeldt, Liting Zhu, Bingshu E Chen, Annette E Hay
Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage chemotherapy was 36%; no difference was observed between dexamethasone, cytarabine, cisplatin (10/30, 33%), and gemcitabine, cisplatin, dexamethasone (11/29, 38%) therapy...
May 15, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28504032/targeting-peroxisome-proliferator-activated-receptors-a-novel-strategy-for-philadelphia-chromosome-positive-leukemia-cells
#20
Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Kazuma Ohyashiki
No abstract text is available yet for this article.
May 15, 2017: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"